Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Nanjing, China's Simcere Pharmaceutical Group reported a slowdown in sales for the second quarter, pointing to intense competition from the spread of Anhui province's tender model for essential drugs and price cuts on products included in the National Drug Reimbursement List
Advertisement

Related Content

Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs
Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
China Pharma And Distributors Suffer From Essential Drug System And Price Cuts
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Advertisement
UsernamePublicRestriction

Register

SC078733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel